These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35086441)

  • 1. The prevalence of atrial fibrillation in Greenland: a register-based cross-sectional study based on disease classifications and prescriptions of oral anticoagulants.
    Albertsen N; Riahi S; Pedersen ML; Skovgaard N; Andersen S
    Int J Circumpolar Health; 2022 Dec; 81(1):2030522. PubMed ID: 35086441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
    Baker D; Wilsmore B; Narasimhan S
    Intern Med J; 2016 Jul; 46(7):792-7. PubMed ID: 27040617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of atrial fibrillation among patients with ischemic stroke.
    Friberg L; Rosenqvist M; Lindgren A; Terént A; Norrving B; Asplund K
    Stroke; 2014 Sep; 45(9):2599-605. PubMed ID: 25034713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.
    Chao TF; Liao JN; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Chen TJ; Lip GYH; Chen SA
    Thromb Haemost; 2019 Jul; 119(7):1162-1170. PubMed ID: 30900222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS
    Chapman SA; St Hill CA; Little MM; Swanoski MT; Scheiner SR; Ware KB; Lutfiyya MN
    BMC Health Serv Res; 2017 Feb; 17(1):127. PubMed ID: 28187730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.
    Alalwan AA; Voils SA; Hartzema AG
    Am J Health Syst Pharm; 2017 Aug; 74(16):1237-1244. PubMed ID: 28652320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
    Mentias A; Shantha G; Chaudhury P; Vaughan Sarrazin MS
    JAMA Netw Open; 2018 Sep; 1(5):e182870. PubMed ID: 30646182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.
    van den Ham HA; Klungel OH; Singer DE; Leufkens HG; van Staa TP
    J Am Coll Cardiol; 2015 Oct; 66(17):1851-9. PubMed ID: 26493655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study.
    Kezerle L; Tsadok MA; Berliner Senderey A; Hoshen M; Leventer-Roberts M; Reges O; Leibowitz M; Haim M
    J Cardiovasc Electrophysiol; 2020 Jun; 31(6):1356-1363. PubMed ID: 32212197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
    Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
    Zhu J; Alexander GC; Nazarian S; Segal JB; Wu AW
    Pharmacotherapy; 2018 Sep; 38(9):907-920. PubMed ID: 29920705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016.
    Adderley NJ; Ryan R; Nirantharakumar K; Marshall T
    Heart; 2019 Jan; 105(1):27-33. PubMed ID: 29991504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation.
    Djukic M; Braun LM; Unkel S; Jacobshagen C; Nau R
    Drugs Aging; 2018 Sep; 35(9):859-869. PubMed ID: 30066299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.